Evidence map›Paper›PMID 39786516›Full record

ArticleEJNMMI research2025

Hepatobiliary scintigraphy and liver function changes in patients with hepatocellular carcinoma treated with

Margot T M Reinders, Maarten J L Smits, Karel van Erpecum, Joep de Bruijne, Rutger C G Bruijnen, Dave Sprengers, Rob de Man, Erik Vegt, Jan N M IJzermans, Marnix G E H Lam and 1 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EJNMMI research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03379844 (Holmium-166-radioembolization in Patients With Unresectable Hepatocellular Carcinoma), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03379844 phase2completednot on this map

Holmium-166-radioembolization in Patients With Unresectable Hepatocellular Carcinoma (HCC); a Multi-center, Interventional, Non-randomized, Non-comparative, Open Label, Early Phase II Study: HEPAR Primary

TypeinterventionalSponsorUMC UtrechtRan2017 to 2021Enrolled30ConditionsHepatocellular Carcinoma, Hepatocellular Carcinoma Non-resectableArmsHolmium-166 radioembolization
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Margot T M ReindersDepartment of Radiology & Nuclear Medicine, University Medical Center Utrecht, Heidelberglaan 100, Utrecht, 3584 CX, the Netherlands.
Maarten J L SmitsDepartment of Radiology & Nuclear Medicine, University Medical Center Utrecht, Heidelberglaan 100, Utrecht, 3584 CX, the Netherlands.
Karel van ErpecumDepartment of Gastroenterology & Hepatology, Utrecht University - University Medical Center Utrecht, P.O. Box 85500 100, Utrecht, 3500 GA, the Netherlands.
Joep de BruijneDepartment of Gastroenterology & Hepatology, Utrecht University - University Medical Center Utrecht, P.O. Box 85500 100, Utrecht, 3500 GA, the Netherlands.
Rutger C G BruijnenDepartment of Radiology & Nuclear Medicine, University Medical Center Utrecht, Heidelberglaan 100, Utrecht, 3584 CX, the Netherlands.
Dave SprengersDepartment of Gastroenterology & Hepatology, Erasmus MC-University Medical Centre, P.O. Box 2040, Rotterdam, 3000 CA, the Netherlands.
Rob de ManDepartment of Gastroenterology & Hepatology, Erasmus MC-University Medical Centre, P.O. Box 2040, Rotterdam, 3000 CA, the Netherlands.
Erik VegtDepartment of Radiology & Nuclear Medicine, Erasmus MC-University Medical Centre, P.O. Box 2040, Rotterdam, 3000 CA, the Netherlands.
Jan N M IJzermansDepartment of Surgery, Erasmus MC-University Medical Centre, P.O. Box 2040, Rotterdam, 3000 CA, the Netherlands.
Marnix G E H LamDepartment of Radiology & Nuclear Medicine, University Medical Center Utrecht, Heidelberglaan 100, Utrecht, 3584 CX, the Netherlands.
Arthur J A T BraatDepartment of Radiology & Nuclear Medicine, University Medical Center Utrecht, Heidelberglaan 100, Utrecht, 3584 CX, the Netherlands. a.j.a.t.braat@umcutrecht.nl.ORCID http://orcid.org/0000-0002-8824-8697

Funding

KWF Kankerbestrijding P10307
6 · The paper itself

Abstract

backgroundTo study the feasibility of hepatobiliary scintigraphy (HBS) to improve selection and planning of patients with hepatocellular carcinoma (HCC) treated with holmium-166 (

resultsThirty-one patients with HCC were included and treated with

conclusionHBS showed that hepatic function and volume significantly decreased in parts of the liver treated with

trial registrationRegistry name: Clinicaltrials.gov. TRIAL NUMBER: NCT03379844. Date of registration: 21 November 2017. Trial URL: https://clinicaltrials.gov/study/NCT03379844?cond=hcc&term=hepar primary&rank=1#study-overview .

Indexed as

Hepatic functionHepatobiliary scintigraphyHepatocellular carcinomaHolmiumLiver clearance rateRadioembolization

Identifiers

PMID39786516
PMCPMC11717772

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.